Armune (Michigan) Receives Accelerate Michigan Innovation Competition $500,000 Grand Prize (12/12/2010)

Armune BioScience, Inc. will develop diagnostic cancer tests that allow for personalized treatment decisions. The company’s technology is based on work performed by University of Michigan Professor of Pathology and Urology Dr. Arul Chinnaiyan, who also chairs the company’s Scientific Advisory Board.

From the company’s home page:
Armune BioScience is pleased to announce that it was awarded the Accelerate Michigan Innovation Competition $500,000 grand prize on Dec 11. The award was presented to Eli Thomssen, President & CEO, following Accelerate Michigan’s 3-day event in Ann Arbor. During the 3-day event, business plans were presented from 50 of the 600 international applications received.

Compendia Bioscience (Michigan) and Althea Diagnostics Develop Breast Cancer Segregation Panel Assay as a Platform for Companion Diagnostic Development (12/8/2010)

Compendia Bioscience provides software to access their collection of cancer genomic information. Compendia Bioscience was co-founded by Daniel R. Rhodes, Ph.D., who is the company’s CEO as well as a part-time faculty researcher at the University of Michigan Center for Translational Pathology, and Arul Chinnaiyan, M.D., PhD., who is a Professor in the Department of Pathology and Urology at the University of Michigan Medical School.

From the company’s press release:
Compendia Bioscience today announced a new strategic partnership with Althea Diagnostics and the immediate availability of the partnership’s first joint product and service offerings — the Breast Cancer Segregation Panel™ Assay and Analysis Service. read full press release

Ascenta Therapeutics (Michigan) and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia (12/6/2010)

Ascenta Therapeutics is a biopharmaceutical company that develops medicines for cancer treatment. The company was co-founded by Dr. Marc Lippman of the University of Miami (and previously at the University of Michigan), Dr. Shaomeng Wang of the University of Michigan, and Dr. Dajun Yang.

From the copmany’s press release:
Ascenta Therapeutics, Inc. and The Leukemia & Lymphoma Society (LLS) today entered into an agreement whereby the LLS will support clinical development of Ascenta’s oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML). read full press release

NanoBio (Michigan) Receives $6 Million to Develop an Intranasal Vaccine for Respiratory Syncytial Virus (RSV) (11/30/2010)

NanoBio is a biopharmceutical company developing products for the treatment of infectious diseases. The company was spun out of the University of Michigan’s Center for Biologic Nantotechnology in 2000. The company was founded by James R. Baker, Jr. M.D., who is Ruth Dow Doan Professor of Medicine and Head of Allergy and Immunology at the University of Michigan as well as Nano Bio’s Executive Chairman and CEO. Dr. Baker invented the NanoStat technology which serves as the platform for NanoBio’s products.

From the company’s press release:
NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV). read full press release

Discera’s (Berkeley, Michigan) Silicon Oscillators Are The First To Deliver 10 ppm Accuracy For Consumer Applications (11/22/2010)

Discera, Inc. develops and markets MEMS-based timing solutions that replace traditional quartz crystals and oscillators. The company was formed in 2001 to commercialize research from the University of Michigan and the University of California at Berkeley. The doctoral work of Chief Technology Officer and Michigan graduate Dr. Wan-Thai Hsu led to the birth of Discera.

From the company’s press release:
Discera, Inc., the leading provider of silicon timing technology announced the production availability of 10 ppm versions of its DSC1001 low jitter and the DSC8001 programmable silicon oscillators. These oscillators are the first silicon timing products to deliver 10 ppm accuracy at up to 85 degrees Celsius as required by ultra-compact and mobile consumer electronics and computing products. They are also the first to deliver this level of performance in a consumer grade product to improve the quality and stability of high definition video applications and wireless communications. Up until now, 10 ppm was only possible for expensive and high power enterprise and carrier grade timing devices. read full press release

Team Michigan came out on top at the inaugural Multi Autonomous Ground-robotic International Challenge (MAGIC 2010) with the help of SoarTech (Michigan) technology (11/19/2010)

SoarTech is a spin-off from the Artificial Intelligence Laboratory of the University of Michigan. The founding team developed the DARPA-funded TacAir-Soar under the leadership of Professor John E. Laird, who is John L. Tishman Professor of Engineering at Michigan.

From the company’s press release:
Teaming with the University of Michigan, SoarTech was recently awarded first place and $750,000 at the first Multi Autonomous Ground-robotic International Challenge (MAGIC 2010). SoarTech’s real-time 3D interface featuring SAGE (Situation, Actions, Goals, Environment) impressed the judges and helped Team Michigan take first in the competition to develop a team of robots that could operate autonomously in urban combat zones. read full press release

Arbor Networks (Michigan) Acquired by Tektronix Communications (8/31/2010)

Arbor Networks is a Michigan-based spinoff developing network security technologies.

Tektronix Communications, a leading worldwide provider of Communications Test and Network Intelligence Solutions, today announced that it has completed the acquisition of Arbor Networks, a leading provider of network security and management solutions for converged carrier networks and next-generation data centers. The terms of the acquisition are not disclosed. [read more]